



Palliative Colorectal Cancer Regimens

The following tables list the evidence-informed regimens (both IV and non-IV) for colorectal a cancer used in the palliative setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors.

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

Colorectal Cancer	
Regimen Code	Regimen Abstract
CAPE	Capecitabine 1000-1250 mg/m ² PO BID days 1-14. Q21 days
CAPE+BEVA	Bevacizumab 7.5 mg/kg IV day 1; Capecitabine 1000 mg/m ² PO BID days 1-14. Q21 days
CAV	Cyclophosphamide 1000 mg/m ² IV day 1; DOXOrubicin 50 mg/m ² IV day 1; vinCRIStine 1.4 mg/m ² IV day 1. Q21 days <i>For Small Cell Carcinoma</i>
CISPETOP(3D)	CISplatin 25 mg/m ² IV days 1-3; Etoposide 100 mg/m ² IV days 1-3. Q21 days <i>For Small Cell Carcinoma</i>
CRBPETOP	CARBOplatin AUC 5 IV day 1; Etoposide 100 mg/m ² IV days 1-3. Q21 days <i>For Small Cell Carcinoma</i>
FLOX	Fluorouracil 500 mg/m ² IV days 1, 8, 15, 22, 29, 36; Leucovorin 500 mg/m ² IV days 1, 8, 15, 22, 29, 36; Oxaliplatin 85 mg/m ² IV days 1, 15, 29. Q56 days
FOLFIRI	Irinotecan 180 mg/m ² IV day 1; Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours day 1. Q14 days

Colorectal Cancer

Regimen Code	Regimen Abstract
FOLFIRI+BEVA	Irinotecan 180 mg/m ² IV day 1; Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; Bevacizumab 5 mg/kg IV day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours day 1. Q14 days
FOLFIRI+PNTM	PANitumumab 6 mg/kg IV day 1; Followed by: Irinotecan 180 mg/m ² IV day 1; Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours, starting on day 1. Q14 days
FU	Fluorouracil 425 mg/m ² IV days 1-5. Q28 days
FU(CIV)	Fluorouracil 1000 mg/m ² /day CIV over 24 hours, days 1-4. Q28 days
FU(CIV-RT)	Fluorouracil 225 mg/m ² CIV over 24 hours daily Concurrent with radiation
FU(IV-CIV)LCVR	Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours day 1. Q14 days
FU(W)	Fluorouracil 500 mg/m ² IV days 1, 8, 15, 22, 29, 36; Q56 days
FULCV(DEGRAMONT)	Leucovorin 200 mg/m ² IV on days 1-2; Fluorouracil 400 mg/m ² on days 1-2; THEN Fluorouracil 600 mg/m ² CIV over 22 hours days 1-2. Q14 days
FULCVR(W)	Fluorouracil 500 mg/m ² IV days 1, 8, 15, 22, 29, 36; Leucovorin 500 mg/m ² days 1, 8, 15, 22, 29, 36. Q56 days
IRIN	Irinotecan 350 mg/m ² IV day 1. Q21 days
IRIN(Q2W)+CETU	Irinotecan 180 mg/m ² IV day 1; Cetuximab 500 mg/m ² IV day 1. Q14 days

Colorectal Cancer

Regimen Code	Regimen Abstract
	<p><i>Alternate schedule:</i> Irinotecan 180 mg/m² IV Day 1. Q14 days Cetuximab 400 mg/m² IV Day 1 CYCLE 1 ONLY, THEN 250 mg/m² IV weekly</p>
IRIN(Wx4)	Irinotecan 125 mg/m ² IV day 1, 8, 15, 22. Q42 days
IRIN(Wx4)+CETU	Irinotecan 125 mg/m ² IV Days 1, 8, 15, 22 Q42 days Cetuximab 400 mg/m ² IV DAY 1 CYCLE 1 ONLY, then 250 mg/m ² IV weekly
IRIN+CETU	Irinotecan 350 mg/m ² IV day 1; Q21 days Cetuximab 400 mg/m ² IV DAY 1 CYCLE 1 ONLY, then 250 mg/m ² IV weekly.
MFOLFOX6	Oxaliplatin 85 mg/m ² IV day 1; Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours day 1. Q14 days
MFOLFOX6+BEVA	Oxaliplatin 85 mg/m ² IV day 1; Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; Bevacizumab 5 mg/kg IV infusion day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours day 1. Q14 days
MFOLFOX6+PNTM	Oxaliplatin 85 mg/m ² IV day 1; Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; PANitumumab 6 mg/kg IV day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours day 1. Q14 days
PNTM	Panitumumab 6 mg/kg IV day 1. Q14 days
RALT	Raltitrexed 3 mg/m ² IV day 1. Q21 days
XELOX	Capecitabine 1000 mg/m ² PO BID days 1-14; Oxaliplatin 130 mg/m ² IV on day 1. Q21 days
XELOX+BEVA	Capecitabine 1000 mg/m ² PO BID days 1-14; Oxaliplatin 130 mg/m ² IV on day 1. Bevacizumab 7.5 mg/kg IV day 1. Q21 days

Colorectal Cancer

Regimen Code	Regimen Abstract
ZOLE	Zoledronic acid 4 mg IV day 1. Q21 days
FOLFIRI+AFLI	Aflibercept 4 mg/kg of IV day 1 – Not currently publicly funded for this regimen and intent THEN Irinotecan 180 mg/m ² IV day 1; Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours day 1. Q14 days
FOLFIRI+CETU	Irinotecan 180 mg/m ² IV day 1; Leucovorin 400 mg/m ² IV day 1; Fluorouracil 400 mg/m ² IV day 1; THEN Fluorouracil 2400 mg/m ² CIV over 46 hours day 1; Cetuximab 400 mg/m² IV day 1, followed by 250 mg/m² IV weekly – Not currently publicly funded for this regimen and intent. Q14 days <u>Alternative schedule for cetuximab:</u> Cetuximab 500 mg/m² IV day 1 – Not currently publicly funded for this regimen and intent. Q14 days
FOLFOXIRI	Irinotecan 165 mg/m ² day 1; Oxaliplatin 85 mg/m² day 1 – Not currently publicly funded for this regimen and intent; Leucovorin 400 mg/m ² day 1; Fluorouracil 3200 mg/m ² CIV over 48-hours day 1. Q14 days
FOLFOXIRI+BEVA	Irinotecan 165 mg/m ² day 1; Oxaliplatin 85 mg/m² day 1 – Not currently publicly funded for this regimen and intent; Leucovorin 400 mg/m ² day 1; Fluorouracil 3200 mg/m ² CIV over 48-hours day 1; Bevacizumab 5 mg/kg – Not currently publicly funded for this regimen and intent Q14 days
FULCVR(W)+BEVA	Fluorouracil 500 mg/m ² IV days 1, 8, 15, 22, 29, 36; Leucovorin 500 mg/m ² days 1, 8, 15, 22, 29, 36; Bevacizumab 5 mg/kg IV infusion every 2 weeks – Not currently publicly funded for this regimen and intent Q56 days
IRINRALT	Irinotecan 300 mg/m ² IV day 1; Raltitrexed 2.6 mg/m² IV day 1 – Not currently publicly funded for this regimen and intent Q21 days

Colorectal Cancer

Regimen Code	Regimen Abstract
IROX	Oxaliplatin 85 mg/m² IV day 1 – Not currently publicly funded for this regimen and intent; Irinotecan 200 mg/m ² IV day 1. Q21 days
OXALRALT	Oxaliplatin 100-130 mg/m ² IV day 1; Raltitrexed 3 mg/m² IV day 1 – Not currently publicly funded for this regimen and intent Q21 days
REGO	Regorafenib 160 mg PO daily days 1-21 – Not currently publicly funded for this regimen and intent Q28 days

Last Updated: November 2017